Guggenheim Forecasts Strong Price Appreciation for argenex (NASDAQ:ARGX) Stock

argenex (NASDAQ:ARGX) had its target price raised by equities research analysts at Guggenheim from $1,135.00 to $1,185.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Guggenheim’s price target would indicate a potential upside of 29.05% from the company’s current price.

Several other analysts also recently issued reports on the company. Wells Fargo & Company raised their price target on argenex from $1,260.00 to $1,291.00 and gave the stock an “overweight” rating in a report on Monday, June 1st. Royal Bank Of Canada upped their price objective on argenex from $890.00 to $945.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. Weiss Ratings raised argenex from a “hold (c)” rating to a “hold (c+)” rating in a research report on Monday, July 6th. Morgan Stanley increased their target price on argenex from $1,170.00 to $1,180.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 24th. Finally, Bank of America raised their target price on argenex from $1,016.00 to $1,088.00 and gave the company a “buy” rating in a research note on Thursday, July 2nd. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,050.50.

argenex Stock Down 0.7%

ARGX opened at $918.22 on Friday. The company’s 50-day moving average price is $868.28 and its 200 day moving average price is $815.12. argenex has a fifty-two week low of $587.37 and a fifty-two week high of $953.58. The firm has a market cap of $57.44 billion, a price-to-earnings ratio of 35.26, a price-to-earnings-growth ratio of 1.13 and a beta of 0.45.

argenex (NASDAQ:ARGX) last issued its earnings results on Tuesday, July 21st. The company reported $7.32 EPS for the quarter, beating analysts’ consensus estimates of $5.86 by $1.46. The company had revenue of $1.54 billion during the quarter, compared to the consensus estimate of $1.45 billion. argenex had a return on equity of 70.27% and a net margin of 32.19%. Research analysts anticipate that argenex will post 26.95 earnings per share for the current year.

Hedge Funds Weigh In On argenex

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Eastern Bank acquired a new stake in argenex in the 2nd quarter valued at approximately $32,000. Sound Income Strategies LLC bought a new stake in argenex during the 4th quarter valued at $28,000. Whipplewood Advisors LLC bought a new stake in argenex during the 1st quarter valued at $28,000. Sunbelt Securities Inc. acquired a new position in argenex during the 3rd quarter worth $36,000. Finally, Axiom Investment Management LLC acquired a new position in argenex during the 1st quarter worth $50,000. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenex News Summary

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenex reported Q2 EPS of $7.32, topping estimates, on revenue of $1.54 billion versus expectations of $1.45 billion, highlighting strong operating momentum and profitability. Q2 earnings report and conference call
• Positive Sentiment: Reuters reported that global sales of Vyvgart jumped in the second quarter, a key driver for argenex’s growth and a major reason the stock has been gaining investor attention. Reuters article on Vyvgart sales
• Positive Sentiment: Oppenheimer, RBC, and Guggenheim all raised price targets and maintained bullish ratings, signaling increased Street confidence in argenex’s growth trajectory and pipeline prospects.
• Positive Sentiment: A Seeking Alpha note highlighted surging profitability, robust cash generation, and operational leverage, while pointing to pipeline catalysts such as empasiprubart as additional upside potential. Seeking Alpha rating upgrade article
• Neutral Sentiment: Short-interest data showed 0 shares reported, which provides little actionable signal for investors because the figures appear unchanged and unusually low.
• Negative Sentiment: Citizens JMP trimmed its price target slightly from $944 to $932, though it still kept a positive rating, making this more of a minor caution than a bearish call.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.